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Alopecia areata (AA) is a genetically determined, immune-mediated disorder of the hair follicle that affects 1%–2% of
the U.S. population. It is defined by a spectrum of severity that ranges from patchy localized hair loss on the scalp to
the complete absence of hair everywhere on the body. In an effort to define the genetic basis of AA, we performed a
genomewide search for linkage in 20 families with AA consisting of 102 affected and 118 unaffected individuals from
the United States and Israel. Our analysis revealed evidence of at least four susceptibility loci on chromosomes 6, 10, 16
and 18, by use of several different statistical approaches. Fine-mapping analysis with additional families yielded a max-
imum multipoint LOD score of 3.93 on chromosome 18, a two-point affected sib pair (ASP) LOD score of 3.11 on
chromosome 16, several ASP LOD scores 12.00 on chromosome 6q, and a haplotype-based relative risk LOD of 2.00 on
chromosome 6p (in the major histocompatibility complex locus). Our findings confirm previous studies of association
of the human leukocyte antigen locus with human AA, as well as the C3H-HeJ mouse model for AA. Interestingly, the
major loci on chromosomes 16 and 18 coincide with loci for psoriasis reported elsewhere. These results suggest that
these regions may harbor gene(s) involved in a number of different skin and hair disorders.
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Alopecia areata (AA [MIM 104000]) is one of the most
common human autoimmune diseases, with a lifetime
risk of ∼2%.1–3 In the United States, 14.5 million people
are affected with AA (National Alopecia Areata Founda-
tion), which affects both sexes at all ages and in all ethnic
groups. It is characterized by patchy hair loss on the scalp
(fig. 1A and 1B), which can eventually involve the entire
scalp, a condition known as “alopecia totalis,” or the en-
tire body, a condition known as “alopecia universalis” (fig.
1C). The onset of the disease can be sudden, its progression
is unpredictable, and it can be recurrent throughout life.
Reports in the literature of overnight whitening of the hair
represent the abrupt onset of AA, since it preferentially
targets pigmented hairs, leaving only white hairs behind
(fig. 1D).4–7 The pathology of alopecia extends far beyond
the physical aspects of hair loss, and it can have a deeply
disturbing psychological impact on affected individuals.8–
10 Even among patients with minimal hair loss from AA,
the loss carries significant emotional and psychological
meaning that not only pertains to hair but also has a pro-
found impact on an individual’s quality of life, ability to
function in society, and preservation of self-esteem, and
it can lead to profound psychological disturbances.8,10
Despite its high prevalence and the inherent visibility
of the phenotype, the pathogenesis of AA is poorly un-
derstood, and there has been significant debate about
whether the primary defect is in the hair follicle, the im-
mune response, or both. Because of the presence of a peri-
bulbar lymphocytic infiltrate in the scalp biopsy speci-
mens of affected patients and the positive response of the
disease to steroid treatment, an autoimmune mechanism
has been postulated for many years, although an autoan-
tigen has not yet been identified.11–16 More recently, at-
tempts to arrive at a unified hypothesis have led to the
description of AA as a tissue-specific autoimmune disease
of the hair follicle.1 The hair follicle is an immune-privi-
leged site, with low levels of major histocompatibility
complex (MHC) expression, and the emerging view is
that AA represents a breakdown in immune privilege and
the subsequent destruction of the hair follicle by T-lym-
phocytes. Thus, AA can be considered a genetically de-
termined, immune-mediated disorder, which therefore
should be amenable to genetic linkage studies.
It is now generally accepted that AA fits the paradigm
of a complex or multifactorial genetic trait, on the basis
of several lines of evidence: (i) its prevalence in the pop-
ulation (∼2%),17,18 (ii) concordance in twins (55%),19 (iii)
a Gaussian distribution of severity,2 (iv) a 10-fold increased
Figure 1. Clinical presentation of AA. A and B, AA appearing as well-circumscribed patches of hair loss on the scalp. C, Alopecia
universalis, the complete form of AA, which leads to absence of all hair on the body. D, AA with selective loss of pigmented hair, with
a patch of white hair left behind. E, Representative examples of pedigree structures of the families with AA. Participating family
members are indicated by an asterisk (*).
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Table 1. Modes of Inheritance and Penetrance Values Used
to Compute MAXHLOD
Genetic
Modela
Penetrancesb
Disease-
Allele
Frequency
Pr(d)cPr(aff/) Pr(aff/d) Pr(aff/dd)
1 .0 .5 .5 .02
2 .0 .8 .8 .01
3 .0 .0 .5 .20
4 .0 .0 .8 .16
a Models correspond to autosomal dominant (models 1 and 2) and
recessive (models 3 and 4) patterns of inheritance, with penetrance
values of 50% (models 1 and 3) and 80% (models 2 and 4).
b A plus sign () p wild-type allele at disease locus; d p disease
allele at disease locus.
c Pr(d) is altered in each model, to maintain a constant prevalence.
Figure 2. Proportion of top 25 scores on a given chromosome
for analysis of pedigrees with AA by use of each of the four test
statistics.
risk for first-degree relatives of affected individuals,2,3,20
and (v) the aggregation of affected individuals in families,
instead of a clear Mendelian pattern of inheritance.2,3 A
systematic search for genetic factors underlying this dis-
order has not been previously undertaken. Additionally,
linkage analysis in complex traits is not exempt from chal-
lenges, because of the characteristic genetic heterogeneity
and the potential presence of numerous susceptibility al-
leles. These factors may be further complicated, in the case
of AA, by the challenges inherent in defining the phe-
notype, exemplified by a range in ages of onset, the some-
times subtle nature of presenting signs, and the waxing-
and-waning nature of the disease.
Until now, genetic studies in AA have been limited to
association analyses, which suggest that a permissive hu-
man leukocyte antigen (HLA) status may potentiate the
development of the disease.12 In early attempts to identify
a genetic component of AA, a number of association stud-
ies with candidate genes have been conducted. Associa-
tion between AA and particular HLA alleles (MIM *604305
and MIM *142860), interleukin-1 (IL1 [MIM *147760 and
MIM *147720]) cluster genes, and the myxovirus resis-
tance 1 gene (MX1 [MIM *147150]), on chromosome 21,
have been suggested (for a review, see the work of Green
and Sinclair2 and McDonagh and Tazi-Ahnini3 and ref-
erences therein). Significant association has been repor-
ted between AA and DQB1*0301 (for severe AA) and
DRB1*1104 alleles.12,21 A family-based study has revealed
that 85% of patients with AA carry DQB1*03 alleles, com-
pared with 46% of controls.22 Those authors also have
shown linkage to HLA-DQB and HLA-DR. Recently, two
new positive associations have been described. The MHC
class I chain-related gene A (MICA [MIM *600169]) has
been identified as both a potential candidate gene and a
part of an extended HLA haplotype that may contribute
to the susceptibility to and severity of AA.23 Additionally,
the gene encoding the lymphoid protein tyrosine phos-
phatase (PTPN22 [MIM *600716]) has been shown to be
associated with severe forms of AA.24
The presence of a perifollicular T-cell infiltrate suggests
an important role for cytokine production in the patho-
genesis of AA. Likewise, it is possible to transfer the disease
with lesional human lymphocytes into an SCID mouse
grafted with human scalp skin.25 Along these lines, several
authors have suggested association between the more se-
vere forms of AA and the IL-1 receptor antagonist gene
(IL1RN [MIM *147679]), in particular, allele IL1RN*2, and
the IL-1 receptor antagonist homologue (IL1F5 [MIM
*605507]).26–28 Furthermore, there is an increased preva-
lence of AA among patients with Down syndrome (MIM
#190685) (9%) compared with among control individuals
(0.1%).29 The MX1 gene maps to chromosome 21 and en-
codes an interferon-inducible protein highly expressed in
lesional anagen hair bulbs from patients with AA. Tazi-
Ahnini et al.30 showed significant association between a
SNP located within MX1, 9,959 bp from the transcription
start site, and patchy AA. Finally, an association between
autoimmune polyglandular syndrome type 1 (APS1 [MIM
#240300]), caused by mutations in the AIRE gene (MIM
*607358), on chromosome 21, and AA has also been re-
ported,31 with AA observed in 37% of patients with APS1.
Despite the genetic associations described above, it is
likely that these alleles account for only part of the genetic
susceptibility to AA. It is noteworthy that cosegregation
with HLA was excluded in two Israeli families.32
A second line of evidence for the genetic basis of AA
comes from the study of animal models. Particularly, the
C3H/HeJ mouse is an inbred laboratory strain that spon-
taneously develops an adult-onset disease that resembles
adult-onset AA in humans. Sundberg et al.33 have identi-
fied four genetic susceptibility loci on mouse chromo-
somes 8 (Alaa3), 9 (Alaa2), 15 (Alaa4), and 17 (Alaa1),
wherein Alaa1 corresponds to HLA orthologs.
The lack of knowledge of the etiology of AA, the psy-
chological impact on the quality of life of patients with
AA, and the absence of an effective treatment underscore
the importance of identifying the mechanisms underlying
the disease. With this in mind, we initiated a compre-
hensive genetic analysis of families with multiple affected
individuals, in search of genes that contribute to the de-
velopment of AA.
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Table 2. Top 15 Results for Four Genetic
Statistical Methods Applied to the 20
Genotyped Pedigrees with AA
Method and
Result Rank Chromosome Locus LOD
MAXHLOD:
1 6 D6S1009 3.554
2 16 D16S753 2.007
3 6 D6S2427 1.707
4 10 D10S1239 1.691
5 2 D2S1776 1.545
6 9 D9S301 1.518
7 1 D1S1612 1.434
8 10 D10S2481 1.384
9 17 D17S1301 1.228
10 6 D6S1270 1.173
11 12 D12S1064 1.129
12 9 D9S930 1.081
13 6 D6S1003 1.068
14 18 D18S976 1.055
15 6 D6S1281 1.034
ASP:
1 6 D6S1009 4.831
2 18 D18S535 2.314
3 6 D6S1003 1.660
4 17 D17S1301 1.388
5 11 D11S1390 1.213
6 17 D17S1293 1.126
7 17 D17S916 .967
8 16 D16S3253 .964
9 6 D6S1040 .919
10 16 D16S403 .915
11 16 D16S753 .899
12 3 D3S2398 .881
13 10 D10S1239 .844
14 2 D2S1776 .820
15 2 D2S1353 .874
ALLSIBS:
1 6 D6S1009 2.762
2 10 D10S2481 1.354
3 2 D2S338 1.340
4 2 D2S1776 1.025
5 10 D10S674 .850
6 1 D1S1612 .845
7 10 D10S1230 .836
8 6 D6S1270 .809
9 6 D6S1056 .775
10 9 D9S930 .755
11 10 D10S1239 .747
12 8 D8S1179 .704
13 11 ATA34E08 .696
14 13 D13S779 .691
15 9 D9S301 .690
TDT:
1 17 D17S1301 1.930
2 9 D9S1122 1.659
3 17 D17S1290 1.505
4 18 D18S535 1.410
5 7 D7S2846 1.389
6 1 D1S1612 1.383
7 1 D1S1595 1.312
8 18 D18S1116 1.245
9 18 D18S976 1.148
10 9 D9S910 1.117
11 18 D18S59 1.115
12 6 D6S1003 .942
13 5 D5S1354 .918
14 16 D16S686 .837
15 1 D1S1597 .820
Material and Methods
Ascertainment of Families
Families were recruited through a patient who received a diag-
nosis of AA. The inclusion criteria required that families have two
or more affected relatives. With this requirement as a starting
point, all family members willing to participate were recruited
for the study. Pedigrees were enrolled from the United States,
primarily through the National Alopecia Areata Registry, and
from Israel. Those family members for whom clinical data were
not available were classified as “unknown” for linkage purposes.
Clinical examiners diagnosed AA in the patients before the
genetic studies. At the time of consultation, blood samples were
drawn and written informed consent was obtained from all par-
ticipants. The study was approved by the local institutional re-
view boards. Overall, 38 pedigrees, consisting of 102 affected and
118 unaffected or unknown individuals who participated in the
study, were collected (examples shown in fig. 1E). On average,
each family contained three affected individuals. The largest ped-
igree, HAA01, originating from Israel, consisted of 22 participat-
ing family members, 10 of whom received a diagnosis of AA (fig.
1E).
Genotyping
Genomic DNA was extracted using the PureGene DNA Isolation
Kit (Gentra Systems). Twenty pedigrees (fig. 1E) were initially ge-
notyped using a semiautomated high-throughput genotyping ap-
proach with fluorescently labeled microsatellite markers.34–36 A
panel of 342 microsatellite markers was used, with an average
marker spacing of 10 cM and an average heterozygosity of 0.77.
Most of the markers were chosen from version 8.0 of the Marsh-
field fluorescence-labeled genome screening set. DNA samples
and PCR reagents were aliquoted with a TECAN Genesis RSP 150
robotic workstation. Multiplex PCR was performed in 384-well
plates (Marsh) in PTC 225 thermocyclers (MJ Research). An av-
erage of 50 ng of genomic DNA was amplified in 10-ml PCRs
containing 0.15–0.2 mM MgCl2, 0.2 mM dNTPs, and 0.5 units of
Taq Platinum polymerase (Invitrogen). The primer concentration
was adjusted (1–50 pmol) to achieve even amplification of each
marker locus contained in the multiplex PCRs. As described else-
where,37 and to improve allele-calling, the last nucleotide of the
reverse, nonfluorescent primer was modified to a guanine to pro-
mote the nontemplated addition of adenine by Taq DNA poly-
merase onto the complementary, fluorescence-labeled strand.
DNA from CEPH control individuals was used as a size standard
for every marker locus. PCR products were electrophoresed on
377 DNA sequencers (PE Applied Biosystems). Raw data from the
PCR products were collected by PRISM 377XL data-collectionsoft-
ware (PE Applied Biosystems), and the products were sized by
GENESCAN version 2.1 and GENOTYPER v.1.1.1. The genotypes
were imported to LABMAN38 for allele binning, Mendelian check-
ing, and generation of linkage files. The PEDCHECK program39
was used to check for genotype errors. The markers that showed
genotype errors were recoded to unknown genotypes in each fam-
ily in which a genotype error was observed. For all multipoint
runs, the MEGA2 program40 was used to format pedigree data for
computation of the likelihood-ratio Z (Zlr) statistics.
As follow-up to the genome scan, fine mapping with micro-
satellite markers was performed by deCODE Genetics for the en-
tire cohort of 38 families. For each marker, the forward primer
was fluorescently labeled. The primer pairs were extensively tested
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Table 3. Summary of Fine-Mapping Results for U.S.,
Israeli, and Combined Pedigrees
Chromosome
and Sample
Maximum
LOD
Position
(cM) Method Marker
6:
U.S. 3.03 138.78 ASP D6S270
Israeli 1.42 142.71 ASP D6S1009
Combined 2.88 142.71 ASP D6S1009
10:
U.S. 1.88 41.4 TDT D10S1661
Israeli 1.63 51.42 HRR D10S2481
Combined 1.63 51.42 HRR D10S2481
16:
U.S. 1.28 69.14 ASP D16S415
Israeli 2.14 65.35 ASP D16S2623
Combined 3.11 69.14 ASP D16S415
18:
U.S. 3.73 21.74 Zlr D18S967
Israeli 1.38 26.03 HRR D18S1163
Combined 3.93 21.74 Zlr D18S967
Figure 3. Results of the fine-mapping study for chromosome 6. A, Region 52.33–54.71 cM. B, Region 134.2–150.93 cM.
for optimizing the multiplex PCR reactions for cost benefits. PCR
amplifications were set up on Zymark ALH 400, were run on MJR
Tetrad, and were pooled on Gilson Cyberlab C200 robots. The
reaction volume was 5 ml, and, for each PCR, 20 ng of genomic
DNA was amplified in the presence of 2 pmol of each primer,
0.25 U AmpliTaq Gold, 0.2 mM dNTPs, and 2.5 mM MgCl2 (buffer
was supplied by the manufacturer, Applera). Cycling conditions
were as follows: at 95C for 10 min, followed by 37 cycles at 94C
for 15 s, annealing at 55C for 30 s, and extension at 72C for 1
min. The PCR products were supplemented with the internal size
standard GS500-LIZ, and the pools were separated and detected
on 3730 Sequencers. Alleles were automatically called using DAC,
an allele-calling program developed at deCODE Genetics,41 and
the program deCODE GT was used to fractionate called geno-
types, according to quality, and to edit, when necessary.42
Six chromosomal regions on four chromosomes (6, 10, 16, and
18) were genotyped, corresponding to the six intervals: (i) the
HLA region on chromosome 6, analyzed using a high-density
panel of 60 microsatellite marker loci at an average marker spac-
ing of 0.09 cM, which spanned the interval flanked by D6S2219
and D6S1560 (2.37 cM); (ii) chromosome 6 interval D6S1040–
D6S1003 (16.72 cM; 12 marker loci); (iii) chromosome 10 interval
D10S674–D10S2481 (10.26 cM; 11 marker loci); (iv) chromosome
10 interval D10S1239–D10S1230 (23.22 cM; 17 marker loci); (v)
chromosome 16 interval D16S403–D16S3098 (60.13 cM; 34
marker loci); and (vi) chromosome 18 interval D18S59–D18S1157
(61.03 cM; 29 marker loci). Marker locations are reported in Hal-
dane map units.
Statistical Analysis
Initial genome scan.—A two-step linkage analysis was performed
on the collection of 38 pedigrees (102 affected and 118 unaffected
participating individuals). In the first stage, a genomewide scan
was conducted for a collection of 20 pedigrees and a total of 131
DNA samples (69 affected and 62 unaffected family members; fig.
1E). The test statistics applied to the data set obtained in the
genomewide scan were (i) the heterogeneity LOD score,43,44 max-
imized over four settings of penetrance parameters (hereafter,
“MAXHLOD”) (see table 1 for the penetrance settings used); (ii)
the mean test for affected sib pairs, as implemented in the AN-
ALYZE program45 (hereafter, “ASP”); (iii) a test of allele sharing
that uses all sibs45 (hereafter, “ALLSIBS”); and a likelihood version
of the transmission/disequilibrium test,46 as developed by Ter-
williger47 (TDT-like, hereafter referred to as “TDT”).
For the ASP test, when there are multiple sibs in a sibship,
ANALYZE weights the sib pairs according to the sibship size, as
follows two sibs equal one sib pair, three sibs equal two sib pairs,
and four sibs equal three sib pairs. As noted by Terwilliger in the
user notes for ANALYZE, “This weighting has been selected to
conform with the information content of phase-unknown nu-
clear pedigrees in linkage analysis.”48(p9) A detailed discussion has
been published.49,50
Our rationale for the use of these different tests was described
elsewhere.51 Briefly, for the MAXHLOD calculations, we applied
a model-based linkage analysis in which the LOD score was cal-
culated under both autosomal dominant and autosomal recessive
patterns of inheritance. For both models, two different values of
penetrance were considered. ASP, ALLSIBS, and TDT tests were
chosen because they are all genetic-model free,52,53 in the sense
that they do not require a specification of the genetic model
parameters (penetrance and disease-allele frequency). MAXHLOD
was chosen because it has been shown that it has at least as much
power to localize disease loci as do ASP and ALLSIBS,54 and, under
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certain circumstances, it is a more precise indicator of the location
of a disease locus than are statistics such as ASP and ALLSIBS.55
Finally, the TDT was chosen because it has been shown that it
may be more powerful than linkage tests (e.g., MAXHLOD, ASP,
and ALLSIBS) when linkage and linkage disequilibrium exist be-
tween a disease and a marker locus.
All results are presented as LOD scores. The TDT P value was
converted to a LOD score by use of the following approximation.
Let P be the P value for the TDT statistic. Because TDT is asymp-
totically distributed as with 1 df, we convert P to a LOD score2x
via the formula , where is the inverse of the one-1 1x (P)/4.6 x
tailed probability of the distribution. An identical conversion2x
was used for the haplotype-based haplotype relative risk (HRR)
minus 2 times n statistic ( ; see the “Fine-mappingHRR 2# n
analyses” section).
Fine-mapping analyses.—For fine-mapping purposes, we focused
on the marker loci that showed significant test scores (the top
10% of scores observed across all marker loci) for at least two of
the test statistics listed above. At this stage, we were more con-
cerned with power than with inflation of the false-positive rate.56
We performed fine-mapping analyses, using two-point and
multipoint genetic model–free statistics. The two-point method
was the ASP test. The multipoint method was the Kong and Cox57
Zlr statistic, which is implemented in the GENEHUNTER-PLUS
software. Although we used affected and unaffected individuals
in our initial genome scan (for the MAXHLOD and ALL-SIB sta-
tistics), we decided to focus on “affecteds-only” statistics in the
fine-mapping analyses. Our reasoning was that the ASP method
was generally more powerful (i.e., yielded higher LOD scores)
than were the MAXHLOD and ALL-SIB statistics. We hypothe-
sized that decrease in power for methods using unaffected indi-
viduals may stem from the fact that they are truly affected but
did not present with symptoms at the time of diagnosis. The TDT
statistic is also an affecteds-only statistic that takes advantage of
any linkage disequilibrium that may occur between marker and
disease locus. We added a family-based test of association, the
HRR.58 The HRR statistic tests for association in the presence of
linkage—unlike the TDT, which tests for linkage in the presence
of association.59 More intuitively, the HRR tests whether the risk
alleles are a single allele or a small set of alleles, whereas the TDT
tests whether recombination between the trait and marker loci
is small (close to 0). Our rationale for using a family-based test
of association was based on the observation that, for several au-
toimmune diseases, associations with the MHC have been de-
scribed, despite weak or no evidence of linkage. This phenome-
non is thought to occur because of the high frequency of the
associated allele, which creates multiple MHC haplotypes among
affected members within families.
We use the version of the HRR, as implementedHRR 2# n
in the ANALYZE program. As Terwilliger notes in the README
notes on the program, “The test performed is that standard
table x2 test, which has df (where there are n alleles2# n n 1
whose frequencies are compared in case and control samples).
This test is less powerful by far when there is only one associated
allele (i.e., linkage disequilibrium from a founder effect), but can
be more sensitive when there are higher order associations with
different alleles.”48(p7) Particularly for the MHC region, we expect
that the latter situation will be true. The case and control samples
for family-based data refer to the transmission of a particular allele
to an affected child (case sample) and the nontransmission of a
particular allele to an affected child (control sample).
Results
Initial Genome Scan
The top 15 scores resulting from each of the four statistical
methods used are presented in table 2. A total of 10 marker
loci resulted in LOD scores 12 (5 are shown in table 2).
Among them, marker D6S1009, at 6q23.3, reached the
highest linkage signal, with a MAXHLOD score of 3.554
and an ASP LOD score of 4.831. Even after correction for
multiple testing, both scores are significant at the .05 level
genomewide.60,61 Moreover, this locus showed the top
score for three of the four statistical methods considered
(table 2). It is interesting to note that several marker loci
appear in the list of top scores for a few of the statistical
methods. Although some of the methods may have cor-
related results,62 they are not identical. Finally, marker loci
D6S1281 and D6S2427, which are located in the vicin-
ity of the HLA region on chromosome 6, were among
the markers with the top 15 MAXHLOD scores (Z pmax
and 1.707, respectively).1.034
Because certain chromosomes appear among the top
scores for at least three of the four statistical methods
applied (table 2), and given that these statistics test dif-
ferent hypotheses, these results point to regions on chro-
mosomes 1, 2, 6, 9, 10, 16, 17, and 18 as potential loci
harboring AA-susceptibility genes.
As an exploratory tool that might indicate which chro-
mosomes harbor susceptibility loci for AA, in figure 2, we
plotted the proportion of the top 25 scores for each test
statistic that appear on a given chromosome. Importantly,
for four chromosomes (6, 10, 16, and 18), at least three
of the four test statistics have at least 8% of their top 25
scores on that chromosome. The 8% value is 4% higher
than the value expected by random selection. Further-
more, if we consider a proportion of0.12, then, for three
chromosomes (6, 10, and 18), three of the four tests have
at least 12% of their top 25 scores on that chromosome.
Thus, the results of the initial genome scan indicate several
suggestive regions of linkage; the most significant LOD
scores were 4.8 on chromosome 6 at marker D6S1009 and
2.3 (for a marker other than D6S1009) on chromosome
18 at marker D18S535.
We performed multipoint linkage analysis, using the
MAXHLOD statistic with the initial genome scan data;
however, none of the multipoint results were as significant
as the two-point MAXHLOD scores. We postulate that this
result stems from the fact that the marker density (10 cM)
was insufficient to benefit from multipoint linkage anal-
ysis (full data not shown).
Fine Mapping
Several authors have defined criteria for declaring sugges-
tive and significant linkage for complex traits, but there
is still controversy about what thresholds should be ap-
plied and how to extend the theoretical situations on
which they are based to real data sets.63–65 Considering this,
we applied the following criteria to the results obtained
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Figure 4. Results of the fine-mapping study for chromosome 10. A, Region 41.19–51.42 cM. B, Region 124.64–147.86 cM.
Figure 5. Results of the fine-mapping study for chromosome 16
in the genome scan, to prioritize the follow-up regions for
the second stage of our study: (i) regions yielding LOD
scores among the top 15 scores for two or more statistical
tests, (ii) marker loci showing LOD scores values 12; and
(iii) chromosomal regions “overrepresented” by having
consecutive or nearly consecutive marker loci among the
top 15 scores for different statistical tests. On the basis of
this algorithm, and to optimize the use of DNA samples,
we chose to first genotype additional marker loci in six
regions on chromosomes 6, 10, 16, and 18 (see the “Ma-
terial and Methods” section for details on the intervals).
The HLA region was included in this second stage on the
basis of the reports of genetic association of AA with dif-
ferent HLA alleles. Regions on chromosomes 1, 2, 9, and
17 will be analyzed in subsequent studies.
The follow-up marker density was increased from 1
marker every 10 cM (in the genome scan) to 1 every 1.82
cM, on average. For the analysis of the HLA region, we
used a high-density panel of microsatellites designed by
deCODE Genetics with marker loci spaced at an average
distance of 0.09 cM (see the “Material and Methods” sec-
tion). Results obtained after genotyping additional micro-
satellite marker loci are plotted in figures 3–6.
Chromosome 6
On chromosome 6, we fine mapped two regions: 52.33–
54.71 cM and 134.2–150.93 cM. In figure 3A and 3B, we
plotted LOD scores for both regions. The largest ASP LOD
score observed on chromosome 6 in the fine-mapping
data occurred at position 142.7 cM (marker D6S1009). The
ASP LOD score at that marker is 2.89. This marker locus
also showed the most significant ASP LOD score in the
original genome scan (table 2). The decrease in signifi-
cance is because of the addition of new families in the
fine mapping, some of which were unlinked to this locus.
It is important to note that the next most significant ASP
LOD scores all occur for marker loci within ∼6 cM of
D6S1009 (fig. 3B). For example, the second-most signifi-
cant ASP LOD score is 2.59, for position 146.8 cM (marker
D6S1569), and the third-most significant ASP LOD score
is 2.31, for position 148.8 cM (marker D6S1684).
The most significant TDT LOD score of 1.9 ( )Pp .0015
occurred at position 54.01 cM (marker D6S2889). As with
the ASP LOD scores, the next five most significant TDT
LOD scores all occurred within 0.5 cM of this position (fig.
3A). Finally, the most significant Zlr LOD score of 1.49
( ) occurred at position 54.6 cM (marker D6S2727),Pp .004
within 0.6 cM of the most significant TDT LOD score.
Another important observation is that the Zlr multipoint
LOD scores are almost always more significant than are
the ASP two-point LOD scores in the region from 52 cM
to 56 cM, whereas the converse is true in the region from
134.2 cM to 150.93 cM (fig. 3A and 3B).
Consideration of the HRR statistic for these data
provided additional information. In particular, marker
D6S273 (position 53.75 cM) showed an HRR LOD score
of 1.99 ( ). This score was the second largestPp .001
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Figure 6. Results of the fine-mapping study for chromosome 18
among HRR LOD scores for all fine-mapping data. It is
interesting to note that this marker is in the MHC locus,
for which previous associations with AA have been
reported.19,22,23,30,66
Chromosome 10
On chromosome 10, we fine mapped two regions: 41.19–
51.42 cM and 124.64–147.86 cM. In figure 4A and 4B, we
plotted the LOD scores for the three statistics for these
two regions. Overall, the highest LOD scores occurred for
three marker loci by use of the ASP statistic. Marker
D10S1239, at position 124.64 cM, showed an ASP LOD
score of 1.50 ( ). Marker D10S254, at positionPp .004
127.08 cM, showed an ASP LOD score of 1.23 ( ).Pp .009
Finally, marker D10S1738, at position 125.15 cM, showed
an ASP LOD score of 0.975 ( ). The largest Zlr LODPp .017
score (0.093; ) occurred at position 47.53 cMPp .064
(marker D10S1734). The largest LOD score for the TDT
method was at position 51.42 cM (marker D10S2481). The
largest HRR LOD at position 51.42 cM (marker D10S2481)
was 1.63 ( ). This score was the third largest amongPp .003
HRR LOD scores for all fine-mapping data.
Chromosome 16
On chromosome 16, we fine mapped the region from 47
cM to 73.82 cM. The most significant result occurred for
marker D16S415, at position 69.14 cM, where we observed
an ASP LOD score of 3.11. The multipoint Zlr LOD score
for the same marker was 0.08, indicating that the two-
point and multipoint results show substantially different
evidence of linkage. The TDT and HRR LOD scores were
generally nonsignficant ( ), with the exception ofP 1 .10
that for marker D16S261 (60.925 cM), which displayed a
TDT LOD score of 0.84 ( ).Pp .02
Chromosome 18
For chromosome 18, we fine mapped the region from 1
cM to 62 cM. The most significant result occurred for
marker D18S967, at position 21.74 cM, where we observed
an Zlr LOD of 3.93 (fig. 6). Relative peaks for the ASP, TDT,
and HRR methods also occurred near this position (fig. 6).
In fact, the Zlr, TDT, and HRR LOD scores for marker
D18S976 (position 16.55 cM) are in the top 10% of the
distribution of LOD scores for each statistic’s distribution
of fine-mapping LOD scores. It is important to note that,
for chromosome 18, the multipoint LOD scores (Zlr values)
increased over the two-point ASP LODs in the region from
∼10 cM to 30 cM.
Stratified Fine-Mapping Analyses
In table 3, we present results of our stratified fine-mapping
analyses for only U.S. pedigrees, only Israeli pedigrees, and
all pedigrees combined. As has been shown in other link-
age studies,67–70 stratification of data by a certain criteria
(e.g., disease diagnosis or ethnic origin) often will increase
linkage information in at least one of the substrata. The
results for all pedigrees combined are included in table 3
for comparison.
The combined results for chromosome 6 are relatively
consistent across all sets of pedigrees. That is, the position
of the maximum LOD score is between 138.78 cM and
142.71 cM, and the maximum LOD score was achieved
using the ASP method. The maximum LOD score increases
to 3.03 when only the U.S. pedigrees are considered, com-
pared with the maximum LOD of 2.88 for all pedigrees
(see also fig. 3B).
We observed similar results for the chromosome 10
analyses. The maximum LOD score increases slightly from
1.63 for the combined set of pedigrees to 1.88 for only
the U.S. pedigrees, and the position of the maximum LOD
shifts from 51.42 cM (combined set) to 41.40 cM (U.S.
pedigrees).
On chromosome 16, the results for the stratified sets
(U.S. and Israeli pedigrees) appear additive. That is, the
combined maximum LOD score of 3.11 is approximately
the sum of the maximum LOD score for the U.S. set (1.28)
and the maximum LOD score for Israeli set (2.14), al-
though the position for the maximum LOD differs by ∼4
cM for the U.S. and Israeli sets.
Finally, for chromosome 18, results of the stratification
suggest that the maximum LOD score of 3.93 for the com-
bined set of pedigrees is largely from the U.S. pedigrees.
The maximum LOD for the only the U.S. pedigrees is 3.73
at the same position (21.74 cM).
Conclusions from the Fine-Mapping Results
Taken together, the fine-mapping results indicated the
strongest evidence of linkage on chromosome 18 in the
region near 21 cM. It is worth noting that the fine-map-
ping analyses of chromosome 18 with additional families
produced significantly larger LOD scores than those from
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the original genome scan, and the maximum multipoint
LOD score of 3.9 is highly significant.
The next strongest evidence of linkage occurred for
chromosome 6 in the HLA region. We see multiple marker
loci with TDT and/or HRR LOD scores 11.5. These results
are not surprising, given that population-based associa-
tion methods have implicated HLA marker loci as being
associated with AA. Although there are some two-point
(ASP) LOD scores 13 for marker loci on chromosome 16,
when the multipoint (Zlr) method is applied, these LOD
scores decrease substantially.
Stratification of pedigrees by ethnic origin resulted in
an increased linkage signal on chromosomes 6 and 10 for
the U.S. pedigrees, no increase in the linkage signal on
chromosome 16, and the observation that the maximum
LOD score for chromosome 18 appears to be from the U.S.
pedigrees. As a methodologic note, the TDT and HRR
methods provided highly correlated results, and, in fact,
the correlation among the TDT and HRR P values (log
transformed) was 0.32 ( for test of correlation).P ! .001
Discussion
The mapping of complex disorders has only recently be-
gun to yield successes in gene identification. The identi-
fication of susceptibility genes for psoriasis and atopic der-
matitis are among the most significant results obtained to
date for complex diseases in dermatology.71–76 One of the
first significant findings in complex-disease mapping was
the identification of alleles predisposing to Crohn disease
(MIM #266600) in the NOD2 gene (MIM *605956).77,78
More recently, an allele of the complement factor H gene
(CFH [MIM *134370]) was significantly associated with
age-related macular degeneration (MIM #153800).79–82 In
all examples, the genetic location of the disease suscep-
tibility locus was first identified by performing genome
scans on families.71,75,83 Subsequent to the linkage analysis,
association studies were used to determine the particular
alleles that confer disease susceptibility. Although many
studies of complex diseases have focused on the collection
of individual cases or sib-pair samples because of the dif-
ficulty of finding a significant number of pedigrees seg-
regating the disease, these types of studies are more vul-
nerable to the effects of genetic heterogeneity and the
polygenic nature of such diseases. Therefore, the identi-
fication of novel disease loci has traditionally been ac-
complished with family-based linkage studies. For this
reason, we chose to approach this first genomewide sus-
ceptibility search of AA by using a collection of pedigrees
with multiple affected individuals. Furthermore, 14 of the
pedigrees originate from Israel, increasing the probability
that they share underlying genetic factors.
The statistical tests used in this study were chosen be-
cause they all are genetic model-free tests,52,53 in the sense
that (with the exception of MAXHLOD) they do not re-
quire a specification of the genetic-model parameters
(penetrance and disease-allele frequency). MAXHLOD is a
parametric linkage analysis in which the LOD score is cal-
culated under autosomal dominant and recessive patterns
of inheritance and penetrance values of 50% and 80%
(table 1). It has been shown that it is at least as powerful
in localizing disease loci as tests like ASP and ALLSIBS54
and is, under certain circumstances, a more precise indi-
cator of the location of a disease locus than are statistics
like ASP and ALLSIBS.55 Several authors have used para-
metric linkage analyses to look for susceptibility loci con-
tributing to complex traits, since, when calculated under
both dominant and recessive models even though they
do not describe the pattern of inheritance of such diseases,
these methods can be a powerful way to localize suscep-
tibility loci.84 Furthermore, these methods can be useful
in a sample like ours, where many of the affected pairs
are not siblings.
TDT was chosen because it has been shown that it may
be more powerful than linkage tests (MAXHLOD, ASP, AL-
LSIBS), when there is linkage and linkage disequilibrium
between a disease and marker locus. Some of the families
with AA collected in Israel are of Ashkenazi and Sephardic
Jewish extraction. These are considered genetically iso-
lated populations, and the extent of linkage disequilib-
rium is therefore thought to extend over larger regions of
the human genome.85,86 Overall, the strategy used to iden-
tify chromosomes of interest for follow-up is similar to
exploratory methods employed by other researchers an-
alyzing genome-scan data for complex traits.87 Previous
authors subdivided the genome into chromosomal bins,
whereas, in this work, we examine whole chromosomes
at a time. We consider the whole chromosome as the unit
of measure because it has been observed, in simulated data
sets, that the methods we employ have better power to
determine the correct chromosome than to determine a
particular subregion of a chromosome harboring a disease-
susceptibility locus.56
In this study, we did not specifically model sporadic
cases, where the probability of being affected given two
copies of the wild-type allele at the disease locus, Pr(aff/
), could carry one or two copies of mutated allele; that
is, Pr(aff/) is perhaps nonzero. However, our previous
research55 suggests that the effect of sporadic cases can be
modeled by locus heterogeneity. Therefore, we used the
MAXHLOD statistic rather than the MAXLOD statistic.
It has been suspected for many years that an autoim-
mune pathogenesis underlies AA, yet firm evidence of an
autoantigen is lacking.11–16 The results of association stud-
ies with HLA in AA suggest a role,12 although perhaps it
explains only a part of the genetic susceptibility to AA.
When compared with the four AA-susceptibility loci iden-
tified in the C3H-HeJ mouse model,33 our results overlap
at the HLA locus. In our data sets, the two marker loci in
the vicinity of the HLA locus yield MAXHLOD values of
1.034 (D6S1281) and 1.707 (D6S2427). The other three
loci in the mouse (on mouse chromosomes 8, 9, and 15)
correspond to regions on 10 different human chromo-
somes (4, 5, 8, 11, 12, 13, 16, 17, 19, and 22). Although
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Figure 7. Comparison of chromosome 18 results with published studies.90,91 Boxes represent regions that showed linkage. Asterisks
(*) indicate marker loci with the highest linkage scores. HSS p hereditary hypotrichosis simplex; PSOR p psoriasis.
the majority of these loci do not correspond to our find-
ings, the region on chromosome 8 does correspond to part
of the region that we fine mapped on human chromosome
16. Since this study represents a first attempt to identify
genetic factors contributing to AA in humans, our results
should be replicated in an independent population. It is
possible that new loci will be identified once the sample
is extended and further suggestive chromosomal regions
are tested, such as those on chromosomes 1, 2, 9, and 17.
Several studies published elsewhere have reported the
association of AA with various genes, including MX1 and
AIRE on chromosome 21 and PTPN22 on chromosome 1.
None of these regions were implicated in our study.
We noted two significant peaks of linkage on chromo-
some 6, one on each arm. The main peak was on 6q (ASP
LOD score 2.89), outside the HLA region. The HLA re-
gion on 6p also showed suggestive linkage (TDT and HRR
LOD score of 1.9), which is consistent with previous
reports.19,22,23,30,66
Two of the regions identified in this study have previ-
ously been implicated in conferring susceptibility to
psoriasis. The region on chromosome 16 was identified in
a genome scan performed on patients with psoriasis
( )88 and also overlaps with a region near aZ p 2.31max
Crohn disease–susceptibility locus.83 On chromosome 18,
we observed consistent linkage peaks 13.0 ( ).Z p 3.93max
This same region of chromosome 18p also contains a pso-
riasis-susceptibility region that was identified indepen-
dently in families from the United Kingdom ( )Zp 1.97
and Finland ( ).89,90 There has also been a reportedZp 3.58
association between deletion of chromosome 18p and
psoriasis vulgaris (fig. 7).66 Interestingly, this same area of
chromosome 18 has also been implicated by linkage in
autosomal dominant hereditary hypotrichosis simplex
( ), although no causative gene has been identifiedZp 3.31
yet.91 Taken together, these lines of evidence suggest that
a gene(s) on chromosome 18p is linked to AA and may
also be involved in other inherited skin and hair disorders.
Understanding the genetic factors underlying AA may
help to elucidate the mechanisms responsible for the dis-
ease, as well as to define at-risk individuals, to improve
the disease prognosis, and to determine its response to
environmental triggers; eventually, it could lead to the
design of new treatment strategies. Initially, the genes in
AA could provide targets for transgenic and knockout
mice, which would be essential for in vivo testing of new
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therapies. Ultimately, it is anticipated that discovery and
modulation of the genes in AA will provide novel thera-
peutic targets for this psychologically devastatingdisorder.
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